Abstract
Objective This study aims to evaluate the clinical value of representative large language models (LLMs), namely ChatGPT, on interpreting seizure semiology to localize epileptogenic zones (EZs) for presurgical assessment in patients with focal epilepsy.
Method We compiled two data cohorts through public sources and a private database respectively. The data cohort compiled from public sources consists of 852 semiology-EZ pairs derived from 193 peer-reviewed journal publications. The private database includes 184 semiology-EZ pairs collected from the Far Eastern Memorial Hospital (FEMH) in Taiwan. ChatGPT was asked to generate the most likely EZ locations based on the semiology records from both cohorts with two prompting methods: Zero-shot prompting (ZSP) and Few-shot prompting (FSP). To evaluate the ChatGPT’s performance compared to epileptologists, a panel of eight epileptologists were recruited for an online survey to provide their interpretations on 100 randomly selected semiology records. The responses from ChatGPT and epileptologists were compared using three metrics: regional sensitivity (RSens), weighted sensitivity (WSens) and net positive inference rate (NPIR).
Results In the evaluation of interpreting seizure semiology, ChatGPT achieved over 80% sensitivity for the frontal and temporal lobes, approximately 40% for the occipital lobe, 20-30% for the parietal lobe, 20% for the insular cortex, and 0% for the cingulate cortex consistently in both data cohorts. By analyzing the responses from epileptologists, ChatGPT-4 outperformed epileptologists in localizing the frontal and temporal lobes, exhibited similar accuracy for the occipital and parietal lobes, but underperformed in the insular and cingulate cortices. Both ChatGPT and epileptologists demonstrated comparable value for WSens and mean of NPIR.
Significance ChatGPT was shown as a clinically valuable tool to assist the decision making in the epilepsy preoperative workup. With ongoing advancements in LLMs, it is anticipated that the reliability and accuracy of ChatGPT will continue to improve in the future.
Competing Interest Statement
Dr. Aboud has served on the advisory board for Servier and is supported in part by the UC Davis Paul Calabresi Career Development Award for Clinical Oncology as funded by the National Cancer Institute/National Institutes of Health through grant #2K12CA138464-11. Dr. Rosenow has received research support from the Federal State of Hesse, specifically at the Center for Personalized Translational Epilepsy Research from 2018 to 2022. Dr. Rosenow has received research support from Chaja-Foundation Frankfurt, focusing on establishing and evaluating the ketogenic diet in institution. Dr. Rosenow received research support from Reiss-Foundation Frankfurt, mainly for the research on the ketogenic diet in GLUT1-DS. Dr. Rosenow received research support from German Ministry of Education, focusing on the ERAPerMed Raise-Genic.
Funding Statement
Research reported in this publication was partially supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, United States under Award Number R21NS135482 (PI: Liu). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Secondary analysis of the anonymized and aggregated data with was approved with IRB waiver at Stevens Institute of Technology.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Added external validation using data from Taiwan. Also updated evaluation metrics and updated all figures
Data Availability
All data produced in the present study are available upon reasonable request to the authors
